Search Results

President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.

One of the lowest paid CEOs in pharma—and one of the only woman leading a top-tier giant—is set to receive up to $27.2 million in 2025.

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives find themselves faced with policy questions ranging from the Inflation Reduction Act to RFK Jr.

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved into a new pharma stratosphere, far eclipsing their rivals.

As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as Eli Lilly offers expanded Zepbound options; and struggling gene therapy biotech bluebird bio goes private in an attempt to stay solvent.

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

X4 Pharmaceuticals today announced that management will be participating in the upcoming H.C. Wainwright 2nd Annual BioConnect Investor Conference, taking place on May 20th, 2024, at the Nasdaq Stock Exchange in New York City.

COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission with a series A raise.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) announced today that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.